Extraintestinale Manifestationen bei Colitis ulcerosa

Definition extraintestinaler Manifestationen bei Colitis ulcerosa

Aussage
Extraintesttinale Manifestationen sind Erkrankungen bei Patienten mit Colitis ulcerosa außerhalb des GI-Traktes, bei denen aufgrund der klinischen Assoziation oder pathogenetischer Mechanismen ein Zusammenhang mit der entzündlichen Darmerkrankung besteht oder vermutet werden muss (C). Hiervon werden extraintestinale Begleiterkrankungen (Gallensteine, Nierensteine) und nicht krankheitsspezifische Komplikationen (Osteoporose, thromboembolische Komplikationen) abgegrenzt (C).

Literatur

• 1 Orchard T R, Wordsworth B P, Jewell D P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.  Gut. 1998;  42 387-391 (IIb)
• 2 Bernstein C N, Blanchard J F, Rawsthorne P. et al . The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.  Am J Gastroenterol. 2001;  96 1116-1122 (IIb)
• 3 Scarpa R, del P uente A, D’Arienzo A. et al . The arthritis of ulcerative colitis: clinical and genetic aspects.  J Rheumatol. 1992;  19 373-377 (IIb)
• 4 de Vlam K, Mielants H, Cuvelier C. et al . Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.  J Rheumatol. 2000;  27 2860-2865 (IIb)
• 5 Palm O, Moum B, Jahnsen J. et al . The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).  Rheumatology (Oxford). 2001;  40 1256-1261 (IIb)
• 6 Jones G, Halbert J, Crotty M. et al . The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.  Rheumatology (Oxford). 2003;  42 6-13 (Ia)
• 7 Freitas J, Farricha V, Nascimento I. et al . Rofecoxib: a possible cause of acute colitis.  J Clin Gastroenterol. 2002;  34 451-453 (IV)
• 8 Van Den Bosch F, Kruithof E, Baeten D. et al . Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.  Arthritis Rheum. 2002;  46 755-765 (Ib)
• 9 Braun J, Brandt J, Listing J. et al . Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.  Lancet. 2002;  359 1187-1193 (Ib)
• 10 Thomas P D, Keat A C, Forbes A. et al . Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy.  Eur J Gastroenterol Hepatol. 1999;  11 1001-1005 (IIa)
• 11 Teixeira W G, da Silva J H, Teixeira M G. et al . Pouchitis: extracolonic manifestation of ulcerative colitis?.  Rev Hosp Clin Fac Med Sao Paulo. 1999;  54 155-158 (III)
• 12 Lohmuller J L, Pemberton J H, Dozois R R. et al . Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis.  Ann Surg. 1990;  211: 622 - 627; discussion 627 - 629 (III)
• 13 Olsson R, Danielsson A, Jarnerot G. et al . Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.  Gastroenterology. 1991;  100 1319-1323 (IIb)
• 14 Parlak E, Kosar Y, Ulker A. et al . Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey.  J Clin Gastroenterol. 2001;  33 299-301 (III)
• 15 Christodoulou D K, Katsanos K H, Kitsanou M. et al . Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature.  Dig Liver Dis. 2002;  34 781-786 (III)
• 16 Kaya M, Angulo P, Lindor K D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.  J Hepatol. 2000;  33 537-542 (III)
• 17 Boberg K M, Fausa O, Haaland T. et al . Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis.  Hepatology. 1996;  23 1369-1376 (III)
• 18 van Buuren H R, van Hoogstraten H JE, Terkivatan T. et al . High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis.  J Hepatol. 2000;  33 543-548 (III)
• 19 Weber C, Krupski G, Lorenzen J. et al . MRCP in primary sclerosing cholangitis.  Fortschr Röntgenstr. 2003; 
• 20 Textor H J, Flacke S, Pauleit D. et al . Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography.  Endoscopy. 2002;  34 984-990 (III)
• 21 Ferrara C, Valeri G, Salvolini L. et al . Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children.  Pediatr Radiol. 2002;  32 413-417 (IIb)
• 22 Burak K W, Angulo P, Lindor K D. Is there a role for liver biopsy in primary sclerosing cholangitis?.  Am J Gastroenterol. 2003;  98 1155-1158 (IIb)
• 23 Beuers U, Spengler U, Kruis W. et al . Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.  Hepatology. 1992;  16 707-714 (Ib)
• 24 Lindor K D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.  N Engl J Med. 1997;  336 691-695 (Ib)
• 25 Harnois D M, Angulo P, Jorgensen R A. et al . High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2001;  96 1558-1562 (Ib)
• 26 Mitchell S A, Bansi D S, Hunt N. et al . A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907 (Ib)
• 27 Baluyut A R, Sherman S, Lehman G A. et al . Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.  Gastrointest Endosc. 2001;  53 308-312 (IIb)
• 28 Stiehl A, Rudolph G, Kloters-Plachky P. et al . Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.  J Hepatol. 2002;  36 151-156 (IIb)
• 29 Tung B Y, Emond M J, Haggitt R C. et al . Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.  Ann Intern Med. 2001;  134 89-95 (IIb)
• 30 Pardi D S, Loftus E V Jr, Kremers W K. et al . Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 889-893 (III)
• 31 Boberg K M, Bergquist A, Mitchell S. et al . Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.  Scand J Gastroenterol. 2002;  37 1205-1211 (III)
• 32 Gregory B, Ho V C. Cutaneous manifestations of gastrointestinal disorders. Part II.  J Am Acad Dermatol. 1992;  26 371-383 (III)
• 33 Greenstein A J, Janowitz H D, Sachar D B. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore); 1976 55: 401-412 (III)
• 34 Tromm A, May D, Almus E. et al . Hautmanifestationen bei chronisch entzündlichen Darmerkrankungen.  Z Gastroenterol. 2001;  39 137-144 (III)
• 35 Veloso F T, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients.  J Clin Gastroenterol. 1996;  23 29-34 (III)
• 36 Regueiro M, Valentine J, Plevy S. et al . Infliximab for treatment of pyoderma gangraenosum associated with inflammatory bowel disease.  Am J Gastroenterol. 2003;  98 1821-1826 (IV)
• 37 Hughes A P, Jackson J M, Callen J P. Clinical features and treatment of peristomal pyoderma gangraenosum.  Jama. 2000;  284 1546-1548 (IV)
• 38 Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangraenosum associated with inflammatory bowel disease.  Isr Med Assoc J. 2004;  6 88-90 (III)
• 39 Latkany P A, Jabs D A. Ocular manifestations of inflammatory bowel disease. In: Bayless TM, Hanauer SB. Advanced therapy of inflammatory bowel disease. London; B.C. Decker 2001: 275-277 (III)
• 40 Soukiasian S H, Foster C S, Raizman M B. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.  Am J Ophthalmol. 1994;  118 601-611 (III)
• 41 de Vries J, Baarsma G S, Zaal M J. et al . Cyclosporin in the treatment of severe chronic idiopathic uveitis.  Br J Ophthalmol. 1990;  74 344-349 (Ib)
• 42 Joseph A, Raj D, Dua H S. et al . Infliximab in the treatment of refractory posterior uveitis.  Ophthalmology. 2003;  110 1449-1453 (IIb)
• 43 Bernstein C N, Leslie W D, Leboff M S. AGA technical review on osteoporosis in gastrointestinal diseases.  Gastroenterology. 2003;  124 795-841 (Ia)
• 44 Ghosh S, Cowen S, Hannan W J. et al . Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis.  Gastroenterology. 1994;  107 1031-1039 (IIb)
• 45 Reffitt D M, Meenan J, Sanderson J D. et al . Bone density improves with disease remission in patients with inflammatory bowel disease.  Eur J Gastroenterol Hepatol. 2003;  15 1267-1273 (IIb)
• 46 Bernstein C N, Blanchard J F, Leslie W. et al . The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.  Ann Intern Med. 2000;  133 795-799 (IIb)
• 47 van Staa T P, Cooper C, Brusse L S. et al . Inflammatory bowel disease and the risk of fracture.  Gastroenterology. 2003;  125 1591-1597 (IIb)
• 48 Vestergaard P, Krogh K, Rejnmark L. et al . Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis.  Gut. 2000;  46 176-181 (IIa)
• 49 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.  Bmj. 1996;  312 1254-1259 (Ia)
• 50 Andreassen H, Rungby J, Dahlerup J F. et al . Inflammatory bowel disease and osteoporosis.  Scand J Gastroenterol. 1997;  32 1247-1255 (IV)
• 51 Vogelsang H, Klamert M, Resch H. et al . Dietary vitamin D intake in patients with Crohn’s disease.  Wien Klin Wochenschr. 1995;  107 578-581 (IIb)
• 52 Bernstein C N, Seeger L L, Anton P A. et al . A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study.  Aliment Pharmacol Ther. 1996;  10 777-786 (Ib)
• 53 Adachi J D, Ioannidis G. Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence?.  Calcif Tissue Int. 1999;  65 332-336 (Ia)
• 54 Buckley L M, Leib E S, Cartularo K S. et al . Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1996;  125 961-968 (Ib)
• 55 Adler G, Reinshagen M. Extraintestinale Manifestationen.  Z Gastroenterol. 2003;  41 54-61 (IV)